Mantle cell lymphoma: 2019 update on the diagnosis, pathogenesis, prognostication, and management
出版年份 2019 全文链接
标题
Mantle cell lymphoma: 2019 update on the diagnosis, pathogenesis, prognostication, and management
作者
关键词
-
出版物
AMERICAN JOURNAL OF HEMATOLOGY
Volume 94, Issue 6, Pages 710-725
出版商
Wiley
发表日期
2019-04-09
DOI
10.1002/ajh.25487
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Survival Outcomes of Younger Patients With Mantle Cell Lymphoma Treated in the Rituximab Era
- (2019) James N. Gerson et al. JOURNAL OF CLINICAL ONCOLOGY
- A phase 1 trial of ibrutinib plus palbociclib in previously treated mantle cell lymphoma
- (2019) Peter Martin et al. BLOOD
- SOX11-negative Mantle Cell Lymphoma
- (2019) Jie Xu et al. AMERICAN JOURNAL OF SURGICAL PATHOLOGY
- SOX11 augments BCR signaling to drive MCL-like tumor development
- (2018) Pei-Yu Kuo et al. BLOOD
- A new molecular assay and genomic complexity predict outcome in conventional and leukemic non-nodal mantle cell lymphoma
- (2018) Guillem Clot et al. BLOOD
- Chronic lymphocytic leukemia and mantle cell lymphoma: crossroads of genetic and microenvironment interactions
- (2018) Xose S. Puente et al. BLOOD
- Long-term outcome analysis of reduced-intensity allogeneic stem cell transplantation in patients with mantle cell lymphoma: a retrospective study from the EBMT Lymphoma Working Party
- (2018) Stephen P. Robinson et al. BONE MARROW TRANSPLANTATION
- Ibrutinib resistance in mantle cell lymphoma: clinical, molecular and treatment aspects
- (2018) Oshrat Hershkovitz-Rokah et al. BRITISH JOURNAL OF HAEMATOLOGY
- Four-year follow-up of a single arm, phase II clinical trial of ibrutinib with rituximab (IR) in patients with relapsed/refractory mantle cell lymphoma (MCL)
- (2018) Preetesh Jain et al. BRITISH JOURNAL OF HAEMATOLOGY
- Increased Susceptibility for Atrial and Ventricular Cardiac Arrhythmias in Mice Treated With a Single High Dose of Ibrutinib
- (2018) Jari M. Tuomi et al. CANADIAN JOURNAL OF CARDIOLOGY
- Complex karyotype in patients with mantle cell lymphoma predicts inferior survival and poor response to intensive induction therapy
- (2018) I. Brian Greenwell et al. CANCER
- Phase 2 trial of bortezomib in combination with rituximab plus hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone alternating with bortezomib, rituximab, methotrexate, and cytarabine for untreated mantle cell lymphoma
- (2018) Jorge E. Romaguera et al. CANCER
- Genomic landscape and prognostic analysis of mantle cell lymphoma
- (2018) Ping Yang et al. CANCER GENE THERAPY
- Strategic Therapeutic Targeting to Overcome Venetoclax Resistance in Aggressive B-cell Lymphomas
- (2018) Lan V. Pham et al. CLINICAL CANCER RESEARCH
- A B-cell receptor-related gene signature predicts survival in mantle cell lymphoma: results from the Fondazione Italiana Linfomi MCL-0208 trial
- (2018) Riccardo Bomben et al. HAEMATOLOGICA
- Acalabrutinib in relapsed or refractory mantle cell lymphoma (ACE-LY-004): a single-arm, multicentre, phase 2 trial
- (2018) Michael Wang et al. LANCET
- Ibrutinib versus temsirolimus: 3-year follow-up of patients with previously treated mantle cell lymphoma from the phase 3, international, randomized, open-label RAY study
- (2018) S Rule et al. LEUKEMIA
- Ibrutinib-associated ventricular arrhythmia in the FDA Adverse Event Reporting System
- (2018) Connie Cheng et al. LEUKEMIA & LYMPHOMA
- Understanding resistance mechanisms to BTK and BCL2 inhibitors in mantle cell lymphoma: implications for design of clinical trials
- (2018) Rishu Agarwal et al. LEUKEMIA & LYMPHOMA
- Ibrutinib plus Venetoclax for the Treatment of Mantle-Cell Lymphoma
- (2018) Constantine S. Tam et al. NEW ENGLAND JOURNAL OF MEDICINE
- Clonal dynamics towards the development of venetoclax resistance in chronic lymphocytic leukemia
- (2018) Carmen D. Herling et al. Nature Communications
- A B-cell receptor-related gene signature predicts survival in mantle cell lymphoma: results from the Fondazione Italiana Linfomi MCL-0208 trial
- (2018) Riccardo Bomben et al. HAEMATOLOGICA
- Ibrutinib, lenalidomide, and rituximab in relapsed or refractory mantle cell lymphoma (PHILEMON): a multicentre, open-label, single-arm, phase 2 trial
- (2018) Mats Jerkeman et al. Lancet Haematology
- Five-year follow-up of lenalidomide plus rituximab as initial treatment for mantle cell lymphoma
- (2018) Jia Ruan et al. BLOOD
- Validation of the MCL35 gene expression proliferation assay in randomized trials of the European Mantle Cell Lymphoma Network
- (2018) Hilka Rauert-Wunderlich et al. BRITISH JOURNAL OF HAEMATOLOGY
- The MCL35 gene expression proliferation assay predicts high-risk MCL patients in a Norwegian cohort of younger patients given intensive first line therapy
- (2018) Harald Holte et al. BRITISH JOURNAL OF HAEMATOLOGY
- Long-term outcomes and mutation profiling of patients with mantle cell lymphoma (MCL) who discontinued ibrutinib
- (2018) Preetesh Jain et al. BRITISH JOURNAL OF HAEMATOLOGY
- Efficacy of venetoclax monotherapy in patients with relapsed, refractory mantle cell lymphoma post BTK inhibitor therapy
- (2018) Toby A. Eyre et al. HAEMATOLOGICA
- A phase 2 study of rituximab, bendamustine, bortezomib and dexamethasone for first line treatment of older patients with mantle cell lymphoma
- (2018) Rémy Gressin et al. HAEMATOLOGICA
- History of autoimmune conditions and lymphoma prognosis
- (2018) Geffen Kleinstern et al. Blood Cancer Journal
- The BTK Inhibitor ARQ 531 Targets Ibrutinib-Resistant CLL and Richter Transformation
- (2018) Sean D. Reiff et al. Cancer Discovery
- Phase Ib trial of an ibrutinib-based combination therapy in recurrent/refractory CNS lymphoma
- (2018) Christian Grommes et al. BLOOD
- Bruton's Tyrosine Kinase degradation as a therapeutic strategy for cancer
- (2018) Dennis Dobrovolsky et al. BLOOD
- CCND2 and CCND3 hijack immunoglobulin light chain enhancers in cyclin D1-negative mantle cell lymphoma
- (2018) David Martín-Garcia et al. BLOOD
- Receiving treatment at a specialist centre confers an overall survival benefit for patients with mantle cell lymphoma
- (2018) Rory McCulloch et al. BRITISH JOURNAL OF HAEMATOLOGY
- Allogeneic haematopoietic cell transplantation impacts on outcomes of mantle cell lymphoma with TP 53 alterations
- (2018) Richard J. Lin et al. BRITISH JOURNAL OF HAEMATOLOGY
- Targeted multigene deep sequencing of Bruton tyrosine kinase inhibitor-resistant chronic lymphocytic leukemia with disease progression and Richter transformation
- (2018) Rashmi Kanagal-Shamanna et al. CANCER
- Frontline bortezomib, rituximab, cyclophosphamide, doxorubicin, and prednisone (VR-CAP) versus rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) in transplantation-ineligible patients with newly diagnosed mantle cell lymphoma: final overall survival results of a randomised, open-label, phase 3 study
- (2018) Tadeusz Robak et al. LANCET ONCOLOGY
- Dynamic molecular monitoring reveals that SWI–SNF mutations mediate resistance to ibrutinib plus venetoclax in mantle cell lymphoma
- (2018) Rishu Agarwal et al. NATURE MEDICINE
- Acquisition of the recurrent Gly101Val mutation in BCL2 confers resistance to venetoclax in patients with progressive chronic lymphocytic leukemia
- (2018) Piers Blombery et al. Cancer Discovery
- Inhibition of focal adhesion kinase overcomes resistance of mantle cell lymphoma to ibrutinib in the bone marrow microenvironment
- (2017) Martina Rudelius et al. HAEMATOLOGICA
- Minimal residual disease in mantle cell lymphoma: are we ready for a personalized treatment approach?
- (2017) Simone Ferrero et al. HAEMATOLOGICA
- New Molecular Assay for the Proliferation Signature in Mantle Cell Lymphoma Applicable to Formalin-Fixed Paraffin-Embedded Biopsies
- (2017) David W. Scott et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase I First-in-Human Study of Venetoclax in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma
- (2017) Matthew S. Davids et al. JOURNAL OF CLINICAL ONCOLOGY
- Smoldering mantle cell lymphoma
- (2017) Haige Ye et al. JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH
- Acalabrutinib (ACP-196): A Covalent Bruton Tyrosine Kinase Inhibitor with a Differentiated Selectivity and In Vivo Potency Profile
- (2017) Tjeerd Barf et al. JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS
- CD200 expression in mantle cell lymphoma identifies a unique subgroup of patients with frequent IGHV mutations, absence of SOX11 expression, and an indolent clinical course
- (2017) Zhihong Hu et al. MODERN PATHOLOGY
- Rituximab after Autologous Stem-Cell Transplantation in Mantle-Cell Lymphoma
- (2017) Steven Le Gouill et al. NEW ENGLAND JOURNAL OF MEDICINE
- Unification of de novo and acquired ibrutinib resistance in mantle cell lymphoma
- (2017) Xiaohong Zhao et al. Nature Communications
- Ibrutinib Unmasks Critical Role of Bruton Tyrosine Kinase in Primary CNS Lymphoma
- (2017) Christian Grommes et al. Cancer Discovery
- Trends and variations in mantle cell lymphoma incidence from 1995 to 2013: A comparative study between Texas and National SEER areas
- (2017) Shuangshuang Fu et al. Oncotarget
- Cytoplasmic cyclin D1 controls the migration and invasiveness of mantle lymphoma cells
- (2017) Simon Body et al. Scientific Reports
- Inhibition of focal adhesion kinase overcomes resistance of mantle cell lymphoma to ibrutinib in the bone marrow microenvironment
- (2017) Martina Rudelius et al. HAEMATOLOGICA
- Minimal residual disease in mantle cell lymphoma: are we ready for a personalized treatment approach?
- (2017) Simone Ferrero et al. HAEMATOLOGICA
- Rituximab, bendamustine, and low-dose cytarabine as induction therapy in elderly patients with mantle cell lymphoma: a multicentre, phase 2 trial from Fondazione Italiana Linfomi
- (2017) Carlo Visco et al. Lancet Haematology
- Pathogenic role of B-cell receptor signaling and canonical NF-κB activation in mantle cell lymphoma
- (2016) Nakhle S. Saba et al. BLOOD
- Postibrutinib outcomes in patients with mantle cell lymphoma
- (2016) P. Martin et al. BLOOD
- Lenalidomide-bendamustine-rituximab in patients older than 65 years with untreated mantle cell lymphoma
- (2016) A. Albertsson-Lindblad et al. BLOOD
- The 2016 revision of the World Health Organization classification of lymphoid neoplasms
- (2016) S. H. Swerdlow et al. BLOOD
- 15-year follow-up of the Second Nordic Mantle Cell Lymphoma trial (MCL2): prolonged remissions without survival plateau
- (2016) Christian W. Eskelund et al. BRITISH JOURNAL OF HAEMATOLOGY
- A phase 2 study of Rituximab-Bendamustine and Rituximab-Cytarabine for transplant-eligible patients with mantle cell lymphoma
- (2016) Philippe Armand et al. BRITISH JOURNAL OF HAEMATOLOGY
- 2016 US lymphoid malignancy statistics by World Health Organization subtypes
- (2016) Lauren R. Teras et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Deferred therapy is associated with improved overall survival in patients with newly diagnosed mantle cell lymphoma
- (2016) Jonathon B. Cohen et al. CANCER
- Decoding the DNA Methylome of Mantle Cell Lymphoma in the Light of the Entire B Cell Lineage
- (2016) Ana C. Queirós et al. CANCER CELL
- Complementarity determining region-independent recognition of a superantigen by B-cell antigen receptors of mantle cell lymphoma
- (2016) M. Fichtner et al. HAEMATOLOGICA
- Prognostic Value of Ki-67 Index, Cytology, and Growth Pattern in Mantle-Cell Lymphoma: Results From Randomized Trials of the European Mantle Cell Lymphoma Network
- (2016) Eva Hoster et al. JOURNAL OF CLINICAL ONCOLOGY
- 18 F-FDG PET for Measurement of Response and Prediction of Outcome to Relapsed or Refractory Mantle Cell Lymphoma Therapy with Bendamustine–Rituximab
- (2016) Dominick Lamonica et al. JOURNAL OF NUCLEAR MEDICINE
- Addition of high-dose cytarabine to immunochemotherapy before autologous stem-cell transplantation in patients aged 65 years or younger with mantle cell lymphoma (MCL Younger): a randomised, open-label, phase 3 trial of the European Mantle Cell Lymphoma Network
- (2016) Olivier Hermine et al. LANCET
- Ibrutinib in combination with rituximab in relapsed or refractory mantle cell lymphoma: a single-centre, open-label, phase 2 trial
- (2016) Michael L Wang et al. LANCET ONCOLOGY
- Lenalidomide versus investigator's choice in relapsed or refractory mantle cell lymphoma (MCL-002; SPRINT): a phase 2, randomised, multicentre trial
- (2016) Marek Trněný et al. LANCET ONCOLOGY
- Epidemiology of Non-Hodgkin's Lymphoma in India
- (2016) Reena Nair et al. ONCOLOGY
- Preclinical Evaluation of the Novel BTK Inhibitor Acalabrutinib in Canine Models of B-Cell Non-Hodgkin Lymphoma
- (2016) Bonnie K. Harrington et al. PLoS One
- CCND1 mutations increase protein stability and promote ibrutinib resistance in mantle cell lymphoma
- (2016) Atish Mohanty et al. Oncotarget
- Complementarity determining region-independent recognition of a superantigen by B-cell antigen receptors of mantle cell lymphoma
- (2016) M. Fichtner et al. HAEMATOLOGICA
- Minimal residual disease in mantle cell lymphoma: insights into biology and impact on treatment
- (2016) E. Hoster et al. Hematology-American Society of Hematology Education Program
- miR-18b overexpression identifies mantle cell lymphoma patients with poor outcome and improves the MIPI-B prognosticator
- (2015) S. Husby et al. BLOOD
- Activity of ibrutinib in mantle cell lymphoma patients with central nervous system relapse
- (2015) S. Bernard et al. BLOOD
- Long-term follow-up of MCL patients treated with single-agent ibrutinib: updated safety and efficacy results
- (2015) M. L. Wang et al. BLOOD
- Rituximab plus hyper-CVAD alternating with MTX/Ara-C in patients with newly diagnosed mantle cell lymphoma: 15-year follow-up of a phase II study from the MD Anderson Cancer Center
- (2015) Dai Chihara et al. BRITISH JOURNAL OF HAEMATOLOGY
- Pharmacological and Protein Profiling Suggests Venetoclax (ABT-199) as Optimal Partner with Ibrutinib in Chronic Lymphocytic Leukemia
- (2015) F. Cervantes-Gomez et al. CLINICAL CANCER RESEARCH
- R-CHOP or R-HyperCVAD With or Without Autologous Stem Cell Transplantation for Older Patients With Mantle Cell Lymphoma
- (2015) Zachary Frosch et al. Clinical Lymphoma Myeloma & Leukemia
- MYC overexpression correlates withMYCamplification or translocation, and is associated with poor prognosis in mantle cell lymphoma
- (2015) Ji-Young Choe et al. HISTOPATHOLOGY
- CD10-positive mantle cell lymphoma: biologically distinct entity or an aberrant immunophenotype? Insight, through gene expression profile in a unique case series
- (2015) Ariz Akhter et al. JOURNAL OF CLINICAL PATHOLOGY
- SOX11 defines two different subtypes of mantle cell lymphoma through transcriptional regulation of BCL6
- (2015) J Palomero et al. LEUKEMIA
- Bortezomib-Based Therapy for Newly Diagnosed Mantle-Cell Lymphoma
- (2015) Tadeusz Robak et al. NEW ENGLAND JOURNAL OF MEDICINE
- Lenalidomide plus Rituximab as Initial Treatment for Mantle-Cell Lymphoma
- (2015) Jia Ruan et al. NEW ENGLAND JOURNAL OF MEDICINE
- Perinucleolar relocalization and nucleolin as crucial events in the transcriptional activation of key genes in mantle cell lymphoma
- (2014) Jeanne Allinne et al. BLOOD
- SOX11 promotes tumor angiogenesis through transcriptional regulation of PDGFA in mantle cell lymphoma
- (2014) J. Palomero et al. BLOOD
- Ibrutinib treatment affects collagen and von Willebrand factor-dependent platelet functions
- (2014) M. Levade et al. BLOOD
- B-cell prolymphocytic leukemia: a specific subgroup of mantle cell lymphoma
- (2014) V. H. J. van der Velden et al. BLOOD
- Ibrutinib increases the risk of atrial fibrillation, potentially through inhibition of cardiac PI3K-Akt signaling
- (2014) J. R. McMullen et al. BLOOD
- A phase 1 study of the PI3K inhibitor idelalisib in patients with relapsed/refractory mantle cell lymphoma (MCL)
- (2014) B. S. Kahl et al. BLOOD
- Randomized trial of bendamustine-rituximab or R-CHOP/R-CVP in first-line treatment of indolent NHL or MCL: the BRIGHT study
- (2014) I. W. Flinn et al. BLOOD
- Racial differences in mantle cell lymphoma in the United States
- (2014) Yu Wang et al. BMC CANCER
- SOX11 and TP53 add prognostic information to MIPI in a homogenously treated cohort of mantle cell lymphoma - a Nordic Lymphoma Group study
- (2014) Lena Nordström et al. BRITISH JOURNAL OF HAEMATOLOGY
- Inhibitors of BCR signalling interrupt the survival signal mediated by the micro-environment in mantle cell lymphoma
- (2014) Sophie Bernard et al. INTERNATIONAL JOURNAL OF CANCER
- A phase II multicenter trial of hyperCVAD MTX/Ara-C and rituximab in patients with previously untreated mantle cell lymphoma; SWOG 0213
- (2013) S. H. Bernstein et al. ANNALS OF ONCOLOGY
- Central nervous system involvement in mantle cell lymphoma: clinical features, prognostic factors and outcomes from the European Mantle Cell Lymphoma Network†
- (2013) C. Y. Cheah et al. ANNALS OF ONCOLOGY
- Egress of CD19+CD5+ cells into peripheral blood following treatment with the Bruton tyrosine kinase inhibitor ibrutinib in mantle cell lymphoma patients
- (2013) B. Y. Chang et al. BLOOD
- SOX11 regulates PAX5 expression and blocks terminal B-cell differentiation in aggressive mantle cell lymphoma
- (2013) M. C. Vegliante et al. BLOOD
- Prognostic impact of monocyte count at presentation in mantle cell lymphoma
- (2013) Kathrin Aprile von Hohenstaufen et al. BRITISH JOURNAL OF HAEMATOLOGY
- microRNA Expression Profiles Identify Subtypes of Mantle Cell Lymphoma with Different Clinicobiological Characteristics
- (2013) A. Navarro et al. CLINICAL CANCER RESEARCH
- Complex karyotype in mantle cell lymphoma is a strong prognostic factor for the time to treatment and overall survival, independent of the MCL international prognostic index
- (2013) Clémentine Sarkozy et al. GENES CHROMOSOMES & CANCER
- Single-Agent Lenalidomide in Patients With Mantle-Cell Lymphoma Who Relapsed or Progressed After or Were Refractory to Bortezomib: Phase II MCL-001 (EMERGE) Study
- (2013) Andre Goy et al. JOURNAL OF CLINICAL ONCOLOGY
- MicroRNA Signature Obtained From the Comparison of Aggressive With Indolent Non-Hodgkin Lymphomas: Potential Prognostic Value in Mantle-Cell Lymphoma
- (2013) Rashmi S. Goswami et al. JOURNAL OF CLINICAL ONCOLOGY
- Obinutuzumab (GA101) Monotherapy in Relapsed/Refractory Diffuse Large B-Cell Lymphoma or Mantle-Cell Lymphoma: Results From the Phase II GAUGUIN Study
- (2013) Franck Andre Morschhauser et al. JOURNAL OF CLINICAL ONCOLOGY
- Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial
- (2013) Mathias J Rummel et al. LANCET
- Pharmacological and genomic profiling identifies NF-κB–targeted treatment strategies for mantle cell lymphoma
- (2013) Rami Rahal et al. NATURE MEDICINE
- Targeting BTK with Ibrutinib in Relapsed or Refractory Mantle-Cell Lymphoma
- (2013) Michael L. Wang et al. NEW ENGLAND JOURNAL OF MEDICINE
- Targeting BTK with Ibrutinib in Relapsed Chronic Lymphocytic Leukemia
- (2013) John C. Byrd et al. NEW ENGLAND JOURNAL OF MEDICINE
- Landscape of somatic mutations and clonal evolution in mantle cell lymphoma
- (2013) S. Bea et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Distribution of Lymphoid Neoplasms in China
- (2012) Jian Sun et al. AMERICAN JOURNAL OF CLINICAL PATHOLOGY
- CCND2 rearrangements are the most frequent genetic events in cyclin D1- mantle cell lymphoma
- (2012) I. Salaverria et al. BLOOD
- Prognostic role of SOX11 in a population-based cohort of mantle cell lymphoma
- (2012) L. Nygren et al. BLOOD
- CHOP and DHAP plus rituximab followed by autologous stem cell transplantation in mantle cell lymphoma: a phase 2 study from the Groupe d'Etude des Lymphomes de l'Adulte
- (2012) R. Delarue et al. BLOOD
- Nordic MCL2 trial update: six-year follow-up after intensive immunochemotherapy for untreated mantle cell lymphoma followed by BEAM or BEAC + autologous stem-cell support: still very long survival but late relapses do occur
- (2012) Christian H. Geisler et al. BRITISH JOURNAL OF HAEMATOLOGY
- Molecular Subsets of Mantle Cell Lymphoma Defined by the IGHV Mutational Status and SOX11 Expression Have Distinct Biologic and Clinical Features
- (2012) A. Navarro et al. CANCER RESEARCH
- Molecular pathogenesis of mantle cell lymphoma
- (2012) Pedro Jares et al. JOURNAL OF CLINICAL INVESTIGATION
- Lenalidomide in combination with rituximab for patients with relapsed or refractory mantle-cell lymphoma: a phase 1/2 clinical trial
- (2012) Michael Wang et al. LANCET ONCOLOGY
- Non-nodal type of mantle cell lymphoma is a specific biological and clinical subgroup of the disease
- (2012) C Royo et al. LEUKEMIA
- Is there a role for antigen selection in mantle cell lymphoma? Immunogenetic support from a series of 807 cases
- (2011) A. Hadzidimitriou et al. BLOOD
- Whole transcriptome sequencing reveals recurrent NOTCH1 mutations in mantle cell lymphoma
- (2011) R. Kridel et al. BLOOD
- Incidence of haematological malignancy by sub-type: a report from the Haematological Malignancy Research Network
- (2011) A Smith et al. BRITISH JOURNAL OF CANCER
- Rituximab plus HyperCVAD alternating with high dose cytarabine and methotrexate for the initial treatment of patients with mantle cell lymphoma, a multicentre trial from Gruppo Italiano Studio Linfomi
- (2011) Francesco Merli et al. BRITISH JOURNAL OF HAEMATOLOGY
- Indolent mantle cell leukemia: a clinicopathological variant characterized by isolated lymphocytosis, interstitial bone marrow involvement, kappa light chain restriction, and good prognosis
- (2011) S. L. Ondrejka et al. HAEMATOLOGICA
- In situ mantle cell lymphoma: clinical implications of an incidental finding with indolent clinical behavior
- (2011) A. Carvajal-Cuenca et al. HAEMATOLOGICA
- Detection of minimal residual disease following induction immunochemotherapy predicts progression free survival in mantle cell lymphoma: final results of CALGB 59909
- (2011) H. Liu et al. HAEMATOLOGICA
- Tumor Necrosis Factor (TNF) and Lymphotoxin- (LTA) Polymorphisms and Risk of Non-Hodgkin Lymphoma in the InterLymph Consortium
- (2010) C. F. Skibola et al. AMERICAN JOURNAL OF EPIDEMIOLOGY
- Incidence of hematologic malignancies in Europe by morphologic subtype: results of the HAEMACARE project
- (2010) M. Sant et al. BLOOD
- Ten-year follow-up after intense chemoimmunotherapy with Rituximab-HyperCVAD alternating with Rituximab-high dose methotrexate/cytarabine (R-MA) and without stem cell transplantation in patients with untreated aggressive mantle cell lymphoma
- (2010) Jorge E. Romaguera et al. BRITISH JOURNAL OF HAEMATOLOGY
- The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy
- (2010) L. A. Honigberg et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Mantle cell lymphoma cells express high levels of CXCR4, CXCR5, and VLA-4 (CD49d): importance for interactions with the stromal microenvironment and specific targeting
- (2009) Antonina V. Kurtova et al. BLOOD
- Patients with chemotherapy-refractory mantle cell lymphoma experience high response rates and identical progression-free survivals compared with patients with relapsed disease following treatment with single agent bortezomib: results of a multicentre phase 2 clinical trial
- (2009) Owen A. O’Connor et al. BRITISH JOURNAL OF HAEMATOLOGY
- Mantle cell lymphoma with central nervous system involvement: frequency and clinical features
- (2009) Saar Gill et al. BRITISH JOURNAL OF HAEMATOLOGY
- Outcome of Deferred Initial Therapy in Mantle-Cell Lymphoma
- (2009) Peter Martin et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase III Study to Evaluate Temsirolimus Compared With Investigator's Choice Therapy for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma
- (2009) Georg Hess et al. JOURNAL OF CLINICAL ONCOLOGY
- Bortezomib in patients with relapsed or refractory mantle cell lymphoma: updated time-to-event analyses of the multicenter phase 2 PINNACLE study
- (2008) A. Goy et al. ANNALS OF ONCOLOGY
- Borrelia infection and risk of non-Hodgkin lymphoma
- (2008) C. Schollkopf et al. BLOOD
- Long-term progression-free survival of mantle cell lymphoma after intensive front-line immunochemotherapy with in vivo-purged stem cell rescue: a nonrandomized phase 2 multicenter study by the Nordic Lymphoma Group
- (2008) C. H. Geisler et al. BLOOD
- Phase 2 trial of rituximab plus hyper-CVAD alternating with rituximab plus methotrexate-cytarabine for relapsed or refractory aggressive mantle cell lymphoma
- (2008) Michael Wang et al. CANCER
- Bendamustine Is Effective in p53-Deficient B-Cell Neoplasms and Requires Oxidative Stress and Caspase-Independent Signaling
- (2008) G. Roue et al. CLINICAL CANCER RESEARCH
- Nuclear expression of the non B-cell lineage Sox11 transcription factor identifies mantle cell lymphoma
- (2007) S. Ek et al. BLOOD
- A new prognostic index (MIPI) for patients with advanced-stage mantle cell lymphoma
- (2007) E. Hoster et al. BLOOD
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started